Late-stage Rituxan trial yields positive results

01/27/2008 | Forbes

Genentech and Biogen Idec on Friday announced that a Phase III study of their monoclonal antibody Rituxan proved the drug safe and effective in improving symptoms in patients with rheumatoid arthritis who failed to respond to methotrexate, a generic anti-rheumatic drug. "These findings support the potential use of Rituxan earlier in the course of treatment for this debilitating disease," a Genentech official said.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY